The FDA has already approved PARP inhibitors in certain patients with metastatic castration-resistant prostate cancer (mCRPC). Now, Johnson & Johnson’s Akeega is giving the class a win in ...
Prevalence of breast cancer across racial, socioeconomic, and regional groups in the US: Analysis of comorbidity distributions using the National Inpatient Sample Database in 2019-2020.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results